A scientist to lead your project, full analytical support to keep it on track, and a veteran team to complete it successfully. That’s the Metrics promise.
Metrics expands with new fast-track product development laboratory and Gerteis Mini-Pactor®.
The path to compliance for USP 232 and USP 233 elemental impurities begins with Metrics three step program.
Metrics delivers pharmaceutical formulation development for routine or complex compounds, first time in man (FTIM) and fast-track development for a variety of dosage forms.
Metrics’ cGMP analytical testing facility has dedicated labs for stability studies, raw materials, trace metals, and microbiology.
Metrics extends its scientist-led development and analytical testing of solid oral dose formulations into manufacturing for Phase I, II and III clinical trial material and commercialization.
Metrics Contract Services has significant experience utilizing CAD technology throughout the drug development process. Let us help with your next project.Learn more
Sending a sample to Metrics?
Use this form to record your sample, storage and testing information.
Dr. Brad Gold, vice president of pharmaceutical development, has received a U.S. patent for his intellectual property about controlled release technology. The U.S. Patent and Trademark Office awarded Gold a patent (No. 8,858,993) for his application, “Coated tablets with zero-order or near zero-order release kinetics.”Learn more
In a feature about analytical testing, Chris Golebiowski, vice president of analytical services, discusses the new USP testing guidelines coming in December 2015.Read article
Along with Gerteis Mini-Pactor®, capital investments reflect ongoing commitment to contract servicesLearn more
Benefits of this new proprietary technology include improved and consistent drug absorption.Learn more
Metrics Inc. now offers proprietary pellet technologies enabling controlled release to help support therapeutic effectiveness of active pharmaceutical ingredients (API).Learn more
Joe Cobb and his team used the principles of QbD to improve the robustness of a core tablet for a novel modified release oral solid dosage form. View the AAPS 2012 poster and watch a short video about how Metrics applies the principles of QbD to solve formulation development issues.Read Poster
Metrics’ potent facility now offers neat API Capsule Filling. The completely contained Xcelodose® could help accelerate clients’ move to Phase I clinical trials.Learn More